Review
Nature Reviews Immunology 2, 116-126 (February 2002) | doi:10.1038/nri727
The B7–CD28 superfamily
Arlene H. Sharpe1 & Gordon J. Freeman2 About the authors
Abstract
The B7-1/B7-2–CD28/CTLA-4 pathway is crucial in regulating T-cell activation and tolerance. New B7 and CD28 molecules have recently been discovered and new pathways have been delineated that seem to be important for regulating the responses of previously activated T cells. Several B7 homologues are expressed on cells other than professional antigen-presenting cells, indicating new mechanisms for regulating T-cell responses in peripheral tissues. Some B7 homologues have unknown receptors, indicating that other immunoregulatory pathways remain to be described. Here, we summarize our current understanding of the new members of the B7 and CD28 families, and discuss their therapeutic potential.
- View At a Glance
Author affiliations
- Immunology Research Divison, Department of Pathology, Brigham, and Women's Hospital and Harvard Medical School, 221 Longwood Avenue, Boston, Massachusetts 02115, USA
- Department of Adult Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
Correspondence to: Arlene H. Sharpe1 Email: asharpe@rics.bwh.harvard.edu
|
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated REFERENCE NEWS AND VIEWS RESEARCH |
